Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases.
Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases. One is the actual cost of the disease and the second is the cost of diagnostic testing. Dr Stefanacci also says that treatments are now currently inexpensive, but with new emerging therapiess the costs will rise.
This video was taken on Thursday, November 8 at the NAMCP Fall Forum in Las Vegas, NV.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen